Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TACo-BEAT-MBM
- 16 Oct 2019 Drug cobimetinib is added in Experimental Arm. Endpoint of Safety, tolerability, and efficacy is added. Planned patient number increased from 40-60.
- 10 Oct 2019 Planned number of patients changed from 40 to 60.
- 10 Oct 2019 Planned primary completion date changed from 1 Jun 2020 to 30 Jun 2020.